Summary. The isolated perfused rat liver can serve as a bioassay system for glucagon, capable of detecting 10 mug of this agent. Seven 15-ml plasma specimens obtained from different healthy volunteers after an overnight fast were assayed in this system; glucagon could not be detected in any of them, indicating concentrations significantly below 0.67 mpg per ml in all subjects.
Introduction
Substantial evidence suggests that glucagon is a hormone playing an essential role in blood glucose homeostasis (1) . Among the studies supporting a physiologic function for glucagon are those of Unger, Eisentraut, McCall, and Madison (2) , showing that glucagon concentrations in the portal system rise in response to hypoglycemia and fall when hypoglycemia is terminated by intravenous glucose injection. These investigators determined plasma glucagon levels by a radioimmunochemical method and reported basal values averaging 0.5 mug per ml in the pancreaticoduodenal veins of dogs after an overnight fast, and a mean value of 2 mug per ml during acute insulin hypoglycemia. Their data are in good agreement with results of studies in our laboratory of the concentrations of glucagon required to induce slight to maximal hepatic glycogenolysis in isolated rat livers (3) .
Recently, there has been considerable interest in utilization of radioimmunochemical assay tech-niques to determine plasma glucagon levels of man. Initial publications on this subject reported quite divergent values for glucagon levels in peripheral blood of normal individuals (4-7), as well as contradictory findings regarding the effects of starvation on the plasma glucagon concentration (4, 6, 7) . A recent research symposium on glucagon (8) failed to clarify this situation; some investigators revised their previously published figures, but no consensus was reached. Average normal values reported by different groups ranged from 0.1 mug per ml of plasma to 5 mug per ml.
Resolution of this controversy among different investigators using similar assay methods, and a decision regarding the order of magnitude of the basal plasma glucagon concentration, are crucial to a proper interpretation of the physiological role of this agent. Since the present controversy centers on the validity of complex radioimmunologic techniques for measurement of glucagon concentration, it seemed desirable to use completely different methods to obtain data that might resolve it. Accordingly, we undertook two series of experiments that offered hope of identifying the order of magnitude of human plasma glucagon levels by measurements of biological activity. One study utilized the isolated perfused rat liver as a bio-778 assay system for glucagon. In previous work with this system, we had demonstrated that the rat liver is quite sensitive to the action of this agent and that several effects can be detected soon after the addition of small amounts of glucagon to the blood perfusing a glycogen-containing liver. These effects include an increase in hepatic phosphorylase activity (9) , an increase in hepatic glucose output (1, 9, 10), a rise in glucose concentration of the perfusing blood (3, 10) , and a fall in hepatic glycogen content (3). The second study was performed with the cooperation of hospitalized patients of this Institute and constituted, in essence, a confirmation of the report of Butterfield, Fry, and Whichelow (11) on the sensitivity of man to small doses of glucagon. Such data constitute indirect evidence from which some conclusions may be drawn regarding the order of magnitude of the basal concentration of glucagon.
Methods
Liver perfusions. The liver perfusion system in use in this laboratory has been described previously (10 by the blood flow rate through the liver, measured at the sampling time, to give the net hepatic glucose output. Liver glycogen was determined by the method of Good, Kramer, and Somogyi (12) using the Autoanalyzer for the determinations of glucose after hydrolysis. Phosphorylase activity was determined in duplicate by a modification of the method of Cahill, Zottu, and Earle (13) . Liver specimens for phosphorylase determination were obtained from sites previously shown to give reproducible values (9) .
Venous blood was obtained with heparinized syringes between 8:30 and 9:30 a.m. from seven healthy adult volunteers who had not eaten since the previous evening. Plasma was separated in a refrigerated centrifuge and stored at 40 C until use (about 2 hours after blood was drawn). Glucagon,l or an equal volume of Ringer's solution, was added to 15 ml of plasma shortly before use. In two experiments, glucagon was added to plasma specimens immediately after centrifugation of the blood, and plasma containing glucagon was allowed to stand at room temperature for 2 hours before use.
Two liver perfusions were performed simultaneously in most experiments. They were started with aliquots from a single pool of normal rat blood. At the end of the base-line periods, human or artificial plasma containing glucagon was added to one system; an equal volume without glucagon was added to the other.
Clinical studies. Glucagon infusions were administered to adult volunteers hospitalized at this Institute. Their diagnoses varied, but none had known diseases of carbohydrate metabolism and all were in good nutritional status. Studies were performed in the morning, after an overnight fast, and breakfast was deferred until completion of glucagon infusion. Physiological saline was infused intravenously at a rate of about 2 ml per minute for 1 hour. Arterialized capillary blood specimens were obtained from warmed fingertips 30, 45, and 60 minutes after starting the infusion. A loading dose of 2.8 isg of glucagon (approximately 1 ,g per L of plasma volume) was then injected through the infusion tubing.' After this, the infusion was changed to physiological saline containing glucagon (0.25 ,tg per ml), which was delivered at a rate of 2 ml per minute. This rate of glucagon infusion was designed to compensate for estimated hepatic inactivation of the agent and was selected on the basis of the following assumptions: that cardiac output was approximately 4 L per minute, that hepatic blood flow was approximately 25% of cardiac output, and that 75%o of the glucagon in blood entering the liver is inactivated during a single passage through this organ (3, 14) . Capillary blood specimens were obtained 5, 15, and 30 minutes after injection of the loading doses.
Results
Liver perfusions. Of a total of 30 liver perfusions, one pair (a control and a glucagon standard) was discarded because the preparations failed 1 vidual values varied over a relatively large range, and there were a number of unexplained fluctuations among successive specimens from the same liver. In about half of the base-line and experimental periods, however, very good agreement was obtained, with all three values falling within 2 U of each other. There were no significant changes in phosphorylase activity during the baseline periods or during the experimental periods in any group of perfusions. Accordingly, the baseline and experimental values in each experiment were averaged, and the differences among the means were compared. The results are shown in Figure 1 . It is evident that addition of 15 ml of human plasma to the perfusing blood did not have a significant effect on hepatic phosphorylase activity. In contrast, the presence of 10 mug of glucagon in artificial plasma, and of 20 mug in human plasma, was readily detected by phosphorylase assay (p < 0.05, p < 0.01, respectively). This assay could not discriminate between the two different dose levels of glucagon, however.
The mean base-line glucose output rates for individual livers varied from small negative values to 0.3 mg per minute per g (Table II) . Despite the unavoidable inaccuracies in calculations based on small differences in glucose concentration, agreement among successive values for individual livers was quite satisfactory; in the majority of perfusions, the maximal variation among the three base-line values did not exceed 0.15 mg per minute per g. Table II also presents the individual values for hepatic glucose output during the experimental periods, as well as the data used to calculate them. For each perfusion, the mean base-line value was subtracted from each experimental value to give the increment in glucose output at each sampling time during the experimental period. Figure 2 presents the means of these increments for the four groups of perfusions. Of interest is the fact that in none of the 10-mug glucagon standard perfusions could a rise in hepatic glucose output be detected at the 81-minute point. In contrast, 4 minutes later, a clear-cut increase (p < 0.01) was seen. By 95 minutes, glucose production was clearly below peak levels. Additions of 15 ml of human plasma did not induce a significant rise in glucose output at any time. When human plasma containing 20 mug of glucagon was added, an increase in hepatic glucose output was demonstrable at 81 minutes (p < 0.01) as well as at 85 minutes (p < 0.01), and the mean rise over the experimental period was significantly greater than that in the lO-mug glucagon standard perfusions (p < 0.05). Thus, in contrast to phosphorylase assay, measurement of the hepatic glucose output proved capable of discriminating between these two groups.
Analysis of the changes in circulating blood glucose concentration confirmed the results of measurement of hepatic glucose output. In each perfusion, the rate of increase in perfusing blood glucose during the experimental period was compared to that during the base-line period. The mean changes during the two time intervals of the experimental period, 81 to 85 minutes and 85 to 95 minutes, are shown in Figure 3 differentiation between the two dose levels of glucagon. The larger amount given with human plasma induced earlier and faster increases in circulating blood glucose than the 10-mig standard addition. The effect of 15 ml of human plasma was clearly less than that of 10 mpug of glucagon (p < 0.01) and was not significantly different from that of artificial plasma (p > 0.05). No significant changes in liver glycogen concentration were observed in any of the experimental groups. There were slight decreases in average glycogen values in the two groups of perfusions to which glucagon had been added, as compared to those in which additions consisted of artificial or human plasma alone. Even when these data were pooled, however, the changes were not statistically significant (p > 0.10).
It was clear from the data presented above that there was less evidence of glucagon action in the group of perfusions with additions of normal human plasma than in the standard group receiving 10 mpg glucagon. To determine whether this was due to a consistently lower concentration of glucagon or to the averaging of figures for a few specimens containing more glucagon with several containing none at all, we reviewed the data from individual perfusions. The results are summarized in Table III . Although some increases in phosphorylase activity, hepatic glucose output, and the rate of rise of blood glucose concentration were seen in the seven experiments with human plasma, there was only one perfusion in which a single change (in phosphorylase activity) exceeded twothirds of the average for the glucagon standard group. This probably reflected experimental variation rather than glucagon effect, since it was also seen twice among the control perfusions. We conclude, therefore, that none of the seven plasma specimens had biologic activity in this system comparable to that of 10 mug of glucagon. (9) , whereas hepatic glucose output can increase more than fivefold (10) . The failure of liver glycogen assays to detect the effects of 10 to 20 mjug of glucagon is consistent with our previous experience in this regard (3) .
These bioassay data indicate that 15 ml of peripheral plasma obtained from healthy adults after an overnight fast contains significantly less than 10 mptg of glucagon (i.e., less than 0.67 mug per ml). Our failure to observe greater effects in this bioassay system cannot be attributed to glucagon antagonists in human plasma or to inactivation of glucagon, since assay after addition of 20 mug of glucagon to equal aliquots of the same plasma specimens uniformly gave the expected results. Review of individual experiments confirmed the results reached from analysis of mean values for the group. None of the seven volunteers studied had plasma glucagon levels detectable by this technique (Table III) .
The results of glucagon administration to patients confirm the report of Butterfield and his colleagues (11) regarding the sensitivity of man to small doses of this agent. They did not use loading doses, but found that an infusion rate of 2 jug per minute produced a progressive increase in blood glucose concentration, with an almost constant slope (about 2 mg per 100 ml per minute) during 20-minute infusions. We observed a similar slope during the first 5 minutes of glucagon administration (Figure 4) . The slower rise during the final 25 minutes of our experiments (Figure 4) is presumably due to the fact that we were using one-fourth of their infusion rate. Of interest is the fact that Butterfield and associates also observed a small increase in blood glucose in a few experiments with a still lower infusion rate, 0.2 jg per minute.
It is impossible to make an accurate estimate of the plasma glucagon level maintained in our experiments or in those of Butterfield and associates.
Our technique of administration was designed to produce an initial increment approaching 1 mug per ml and to ensure that this was not exceeded at any time thereafter. However, it is very unlikely that such an increment was maintained for more than a minute or two, if it was reached at all. Glucagon has a space of distribution much larger than the blood volume and disappears from the plasma very rapidly (14) . Thus, even if our 784 infusion rate were somewhat greater than the rate of hepatic inactivation, the plasma concentration would have fallen after injection of the loading dose. Since the blood glucose concentration continued to rise after the first 5 minutes in all but one of our subjects, it would appear that hepatic glycogenolysis can be stimulated by increments significantly less than 1 mpug per ml. This conclusion is supported by the observation of Butterfield and colleagues that infusion at a rate of 0.2 pg per ml could induce an increase in blood glucose. Thus, the sensitivity of human liver to glucagon action is probably not greatly different from that of rat liver (3), cat liver (15) , and dog liver (16) .
If, as seems to be the case, man responds to glucagon in a manner similar to that of other mammalian species so far studied, a portal vein concentration of 1 mpg per ml would induce a rate of glycogenolysis much more rapid than that associated with the basal state. The present studies, plus previous experience with rat liver in this laboratory (3, 9) (8) . However, one group working with radioimmunoassays has recently reported concentrations in peripheral plasma of ten fasting normal subjects ranging from undetectable levels to a maximum of 0.3 mpg per ml (17) . These values are in or near the range suggested above. Thus, it appears that bioassay and immunoassay results are not necessarily irreconcilable.
